SEC Form 4 · accession 0001384101-19-000030
VERACYTE, INC. · VCYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Giulia C Kennedy
Officer — Chief Scientific & Med Officer
Period of report
Mar 4, 2019
Accepted (ET)
Mar 5, 2019 · 4:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001384101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 4, 2019 | M | 17,625 | $5.98 | A | 66,249 | D | |
| Common StockF1 | Mar 4, 2019 | S | 17,625 | $20.2388 | D | 48,624 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $5.98 | Mar 4, 2019 | M | 17,625 | D | — | Mar 1, 2028 | Common Stock | 17,625 | 52,875 | D |
Explanation of responses
- F1Represents weighted average sales price. Sale prices for the transactions range from $20.00 to $20.77. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- F2The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.